83 related articles for article (PubMed ID: 37205431)
1. Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy.
Moradbeygi F; Ghasemi Y; Farmani AR; Hemmati S
Biomed Pharmacother; 2023 Oct; 166():115292. PubMed ID: 37579696
[TBL] [Abstract][Full Text] [Related]
2. Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.
Hiltensperger M; Krackhardt AM
Front Immunol; 2023; 14():1121030. PubMed ID: 36949949
[TBL] [Abstract][Full Text] [Related]
3. Host-cell Interactions of Engineered T cell Micropharmacies.
Bourne CM; Wallisch P; Dacek M; Gardner T; Pierre S; Vogt K; Corless BC; Bah MA; Romero Pichardo J; Charles A; Kurtz KG; Tan DS; Scheinberg DA
bioRxiv; 2023 May; ():. PubMed ID: 37205431
[TBL] [Abstract][Full Text] [Related]
4. Host Interactions with Engineered T-cell Micropharmacies.
Bourne CM; Wallisch P; Dacek MM; Gardner TJ; Pierre S; Vogt K; Corless BC; Bah MA; Romero-Pichardo JE; Charles A; Kurtz KG; Tan DS; Scheinberg DA
Cancer Immunol Res; 2023 Sep; 11(9):1253-1265. PubMed ID: 37379366
[TBL] [Abstract][Full Text] [Related]
5. SEAKER cells coordinate cellular immunotherapy with localized chemotherapy.
Lane IC; Jan M
Trends Pharmacol Sci; 2022 Oct; 43(10):804-805. PubMed ID: 35491262
[TBL] [Abstract][Full Text] [Related]
6. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
[TBL] [Abstract][Full Text] [Related]
7. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
8. A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies.
Klatt MG; Dao T; Yang Z; Liu J; Mun SS; Dacek MM; Luo H; Gardner TJ; Bourne C; Peraro L; Aretz ZEH; Korontsvit T; Lau M; Kharas MG; Liu C; Scheinberg DA
Blood; 2022 Aug; 140(8):861-874. PubMed ID: 35427421
[TBL] [Abstract][Full Text] [Related]
9. Engineering CAR-T cells to activate small-molecule drugs in situ.
Gardner TJ; Lee JP; Bourne CM; Wijewarnasuriya D; Kinarivala N; Kurtz KG; Corless BC; Dacek MM; Chang AY; Mo G; Nguyen KM; Brentjens RJ; Tan DS; Scheinberg DA
Nat Chem Biol; 2022 Feb; 18(2):216-225. PubMed ID: 34969970
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.
Peraro L; Bourne CM; Dacek MM; Akalin E; Park JH; Smith EL; Scheinberg DA
Mol Ther; 2021 Dec; 29(12):3398-3409. PubMed ID: 34217891
[TBL] [Abstract][Full Text] [Related]
11. Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy.
Charles A; Bourne CM; Korontsvit T; Aretz ZEH; Mun SS; Dao T; Klatt MG; Scheinberg DA
Oncoimmunology; 2021 May; 10(1):1916243. PubMed ID: 34104540
[TBL] [Abstract][Full Text] [Related]
12. Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery.
Gardner TJ; Bourne CM; Dacek MM; Kurtz K; Malviya M; Peraro L; Silberman PC; Vogt KC; Unti MJ; Brentjens R; Scheinberg D
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764348
[TBL] [Abstract][Full Text] [Related]
13. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.
Coughlan L
Front Immunol; 2020; 11():909. PubMed ID: 32508823
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
